NautaDutilh advises atai Life Sciences in its USD390m business combination with Beckley Psytech and USD30m concurrent private placement.
NautaDutilh has acted alongside Latham & Watkins in advising atai Life Sciences N.V. (atai) in its acquisition of all shares of Beckley Psytech (Beckley) not already held by atai, in exchange for the issuance by atai of approximately 105 million new shares to Beckley shareholders, valuing Beckley at approximately USD390 million. Concurrent with the transaction, atai also executed USD30.0 million private placement with Ferring Ventures S.A. and Adage Capital Partners LP. This financing is not contingent on closing of the transaction with Beckley.
“We are excited to have represented atai on achieving this pivotal milestone in delivering on its strategic vision and creating a market leader at the forefront of psychiatric care.”
The core NautaDutilh team also included Nina Kielman, Stefan Wissing, Joppe Schoute, Marloes van der Laan, Eline van Marle, Leanne Meurs and Daphne Smiggels.
